Histopathological Characterization of the Skeletal Myopathy in rasH2 Mice Carrying Human Prototype c-Ha-ras Gene

Abstract

ABSTRACT. A skeletal myopathy is found in approximately 100% of rasH2 mice. To confirm detailed features of the rasH2 skeletal myopathy, the biceps femoris, diaphragm, triceps brachii, gastrocnemial (types I and II fiber-mixed muscles) and soleus muscle (type I fiberdominant muscle) obtained from male rasH2 and non-transgenic littermates aged 10-13 and 34 weeks were examined. Variations in the muscle fiber size, early-scattered degeneration/necrosis and regeneration of muscle fibers were detected in 10-13-week-old rasH2 mice. The severity of the above muscular lesions was more prominent in older rasH2 mice. These lesions were noted in the type II myofiber dominant muscles (biceps femoris, triceps brachii and gastrocnemial). NADH-TR stain clearly demonstrated a disorganized intermyofibrillar network and necrotic change in muscle fibers. No specific morphological changes, like rod structure or tubular aggregation seen in some types of myopathy, were noted in Gomori trichrome and NADH-TR stains in the rasH2 mouse like in many types of muscular dystrophy. Electronmicroscopically, occasional muscle fiber degeneration/regeneration, invaded phagocytic cells, indistinct Z-band suggesting excessive contraction and dilatation of the sarcoplasmic reticulum were observed. In summary, the skeletal myopathy occurring in rasH2 mice is consistent with muscular dystrophy characterized morphologically by progressive degeneration and regeneration of myofibers. The myopathy is confined to the type II myofiber predominant muscles and is not associated with any pathognomonic lesions. These characteristics will provide us with a useful model for research in muscular dystrophy of diverse myofibers. KEY WORDS: histopathology, rasH2 mouse, skeletal myopathy.

MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model

“…A few mouse models have explored the effect of activated Ras/MAPK on skeletal muscle development, including a mouse model for NF1 (Brannan et al, 1994;Kolanczyk et al, 2007), a homozygous knockout model for Dusp1 (Shi et al, 2010), a mouse model with a homozygous knockout of both Spry1 and Spry2 (Michailovici et al, 2014), a cancer mouse model that carries multiple genomic copies of human oncogenic HRAS (Tsuchiya et al, 2005) and, most recently, a mouse model of CFC harboring an intermediate-activating Braf allele (Maeda et al, 2021). All of these models demonstrated disrupted muscle development to varying degrees.…”

A 26-Week Carcinogenicity Study of 2-Amino-3-Methylimidazo[4,5-f]Quinoline in rasH2 Mice

“…In rasH2 mice, skeletal myopathy, which is characterized by variation in muscle fiber size, centrally placed nuclei, regenerating fibers, and interstitial fibrosis, has been reported to be a spontaneous histopathological lesion with no difference with respect to gender (Tsuchiya et al, 2002). The myopathic changes were observed with aging and were detected in almost 100% of 34-week-old rasH2 mice (Tsuchiya et al, 2002; Tsuchiya et al, 2005). Although the integration of the c-Ha- ras gene is thought to be crucial, the underlying mechanism of its pathogenesis remains to be elucidated.…”

Ras/MAPK dysregulation in development causes a skeletal myopathy in an activating BrafL597V mouse model for cardio‐facio‐cutaneous syndrome

“…The role of Ras/MAPK pathway dysregulation in skeletal muscle was additionally demonstrated in a cancer mouse model that carried multiple genomic copies of human oncogenic HRAS. These mice exhibited a primary skeletal myopathy characterized by variable muscle fiber size and muscle degeneration 19 …”